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a-SynucleinAggregation of a-synuclein is a pathological hallmark of sporadic or familial PD. However, the
detailed molecular mechanism responsible for the aggregation of a-synuclein has not been properly
explored. In the present study, we have identiﬁed a novel role of an anti-tumorigenic BTB/POZ
domain containing protein-2 (BPOZ-2) in the regulation of a-synuclein accumulation in dopaminer-
gic (DA) neurons. MPP+, an etiological factor for PD, signiﬁcantly downregulated the expression of
BPOZ-2 ahead of a-synuclein upregulation. Moreover, siRNA knockdown of BPOZ-2 alone stimu-
lated the aggregation of a-synuclein protein; the effect was further induced in presence of MPP+
in mouse primary DA neurons. Finally, the absence of BPOZ-2 in a-synuclein expressing neuronal
populations of MPTP-intoxicated mouse and primate nigra indicates that the suppression of
BPOZ-2 could be involved in the accumulation of a-synuclein protein.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
BTB/POZ domain containing protein is a growth suppressor
protein [1] that mainly participates in protein–protein interaction
with E3 ubiquitin ligase [2]. Its role as a scaffold protein mainly
stems from the presence of ankyrin repeats (ARs) and two BTB/
POZ domains that render BPOZ to function as an interface between
two proteins [3]. BPOZ has three spliced variants named as BPOZ-1,
2, and 3 [4]. BPOZ-2 has two ARs, BPOZ-3 has one and BPOZ-1 has
no AR. Evidently, BPOZ has been reported to interact with E3 ubiq-
uitin ligase via its BTB domain and its interaction with one such E3
ubiquitin ligase Cul-3 [2] has been shown to arrest the growth of
tumors. As a mechanism, the overexpression of BPOZ has been re-
ported to arrest the transition of cell cycle from G1 to S phase [5].
Although, its role in the tumor biology is currently being studied,
nothing is known regarding its involvement in the pathogenesis
of neurodegenerative disorders. Among all three BPOZ proteins,
BPOZ-1 and 2 has been shown to be present ubiquitously in the
different parts of the brain.
Aggregation of a-synuclein is not only the hallmark of sporadic
PD [6], but a reliable diagnostic marker of classical PD [7] as well.
The a-synuclein containing Lewy bodies have been shown to beinvolved in the loss of DA neurons [8,9] in all form of PD. Although,
the mechanism of a-synuclein aggregation is not clearly under-
stood, the dysfunction of parkin, an E3 ubiquitin ligase, could be
associated in the inhibition of the proteasomal degradation of
a-synuclein protein leading to the formation of a-synuclein aggre-
gates [10]. Recent studies indicate that the nitrosylation of parkin
inhibits its catalytic activity [11], albeit its direct effect in the
accumulation of a-synuclein is yet to be explored. Since, BPOZ con-
trols the activity of E3 ubiquitin ligase protein, our present study
explores if BPOZ has any role in the proteasomal degradation of
a-synuclein aggregates in the nigra of MPTP-intoxicated mouse
brain of PD. Our results clearly showed that the expression of BPOZ
protein and mRNA was strongly downregulated in the MPP+-trea-
ted DA neuronal culture as well as MPTP-treated mouse nigra. Our
results further demonstrated that the selective knockdown of
BPOZ-2gene sufﬁciently stimulated the aggregation of a-synuclein
protein without altering the mRNA expression of snca gene indicat-
ing its direct and posttranscriptional role for the possible turnover
of a synuclein aggregates.
2. Result
2.1. BPOZ-2 could be involved in the inhibition of a-synuclein
aggregation in mouse primary DA neurons
MPP+ is the etiological toxin of Parkinson’s disease that has
been reported to induce the expression of a-synuclein [12,13]
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cytoplasmic proteinaceous inclusions with other cytoskeletal
proteins, which eventually paralyze the cellular metabolic process
and ﬁnally cause the death of DA neurons [14]. Since, BPOZ-2 plays
an important role in the clearance of protein in other cell types
[4,5], we ﬁrst wanted to study if BPOZ-2 was at all expressed in
DA neurons. Interestingly, we have observed that DA neurons
strongly express BPOZ-2 mRNA (Fig. 1A and B) and protein
(Fig. 1C and D). Moreover, the expression of that protein isFig. 1. Temporal relationship between BPOZ-2 and a-synuclein aggregation in MPP+-stim
E14 DA neurons were treated with increasing doses of MPP+ for 1 h and then tested for m
quantiﬁed with the realtime quantitative mRNA expression assay (B). aP < 0.05 vs. con
expression was quantiﬁed with increasing doses of MPP+ after 12 h of stimulation with
control BPOZ-2 protein (E) Next, mouse primary neurons were analyzed for BPOZ-2 mRN
realtime quantitative mRNA expression analyses of this time dependent experiment.
normalized with the GAPDH expression from respective samples. (G) DA neurons were im
with 5 lMMPP+. (H) The plot represents the relative density of BPOZ-2 expression as sho
aP < 0.01 vs. control BPOZ-2 mRNA. (I) The protein expression of a-synuclein was analyze
with the relative density analysis (J). Yellow bars represent the band densities of 100 Kda
synuclein proteins normalized with respective b-actin bands. aP < 0.005 vs. a-syn poly
simulates the expression of a-synuclein protein with its increasing time points that was
of 40 Kda a-syn dimeric bands whereas red bars represent monomeric bands. aP < 0.01 v
±S.D. of three independent experiments. GAPDH = Glyceraldehyde-3-Phosphate Dehydrosigniﬁcantly disturbed in the presence of Parkinsonian toxin
MPP+ (Fig. 1A–F) as we found that MPP+ inhibited the mRNA
expression of BPOZ-2 with increasing doses (Fig. 1A and B) and
time (Fig. 1E and F) suggesting the possible role of BPOZ-2 in the
protection of DA neurons. However, the expression of BPOZ-1, an-
other bpoz family protein, was not altered with the increasing con-
centrations of MPP+ (Fig. 1A and B) suggesting the speciﬁc role of
BPOZ-2 in the protection of DA neurons. The strongest effect on
BPOZ-2 mRNA expression was observed at 45 min of stimulationulated mouse primary dopaminergic neurons. (A) In a dose-dependent study, mouse
RNA expression analyses of BPOZ-2 and BPOZ-1. Our mRNA analyses were further
trol mRNA expression of BPOZ-2. (C) Similar to mRNA analyses, BPOZ-2 protein
MPP+ and that was further evaluated with a relative density plot (D). aP < 0.005 vs.
A expression at 0, 30, 45, 60, and 120 min after stimulation with 2 lMMPP+. F is the
aP < 0.01 vs. control BPOZ-2 mRNA. In all cases, mRNA expression analyses were
munoblotted for BPOZ-2 protein expression after 0, 2,6,12, and 24 h of stimulation
wn in (G), measured as a ratio of BPOZ-2 and the respective beta-actin band density.
d in DA neurons at 1, 2, and 5 lM of MPP+ stimulation for 72 h and further evaluated
bands normalized with actin and red bars represent the monomeric expression of a-
mers in control cells and bP < 0.05 vs. a-syn monomer in control cells. (K) MPP+
further conﬁrmed by densitometric analyses (L). Yellow bars show relative densities
s. a-syn in control cells and bP < 0.005 vs. a-syn oligomer in control cells results are
genase.
A. Roy, K. Pahan / FEBS Letters 587 (2013) 3567–3574 3569(Fig. 1E and F) with a dose of 5 lM of MPP+ (Fig. 1A and B). Accord-
ing to our time dependent study, the mRNA expression of BPOZ-2
was completely abrogated at 2 h of stimulation with MPP+
(Fig. 1B). Similarly, our immunoblot analyses revealed that MPP+
inhibited the protein expression of BPOZ-2 with its increasing con-
centration (Fig. 1C) and time (Fig. 1G) with the lowest expression
was achieved at 5 lM concentration and after 12 h of stimulation.
The effect was further quantiﬁed by densitometric analyses as de-
scribed under method section (Fig. 1D and H). Interestingly, in a
similar dose (Fig. 1I and J) and time gradient (Fig. 1K and L) studies,
we have detected the signiﬁcant level of polymerized form of a-
synuclein protein after 72 h of incubation of 5 lMMPP+ as evident
from our immunoblot analyses. The appearance of multiple high
molecular weight bands between 60 and 100 Kda indicates the
presence of polymerized a-synuclein molecules. However, the
expression of 17 Kda monomeric a-synuclein protein was margin-
ally upregulated in all different conditions as shown in our densi-
tometric analyses (Fig. 1J and L) indicating that MPP+ is primarily
involved in the post-translation aggregation of a-synuclein
molecules with trivial stimulation of transcription of sncagene.
The dose responsive analysis revealed that the aggregation of0
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Fig. 2. Immunocytochemical analyses of BPOZ-2 and aggregated a-synuclein in MPP
stimulated with 5 lM of MPP+ for 0, 6, 12, and 24 h and then analyzed by immunocytoc
stained with a-synuclein (green) and TH (red) after 0, 48, 72, and 96 h of MPP+ stimulatio
synuclein (D) were analyzed by the microsuite 5 software of Olympus microscope. (E) His
respect to total number of DAPI-stained cells. (F) Histogram analyses of the percent of a-s
in different time points.a-syn (Fig. 1I and J) protein started at l lM concentration and
reached maximum at 5 lM concentration. On the other hand, our
time dependent analysis demonstrated that the aggregation
started at 72 h of incubation peaking maximum at 96 h of MPP+
incubation (Fig. 1K and L). Similarly, our immunoﬂuorescence
analysis revealed that the expression of BPOZ-2 was strongly
downregulated at 6 h of stimulation reaching minimum at 12 h
of stimulation with MPP+ (Fig. 2A). Next we investigated the
appearance of a-synuclein accumulation in DA neurons in the
presence of MPP+. The aggregated form of a-synuclein protein
was observed to be appeared as a punctuated green signal at
72 h with maximum at 96 h of stimulation with MPP+ (Fig. 2B).
The effect was further supported with mean ﬂuorescence intensity
analyses as we observed that the load of BPOZ-2 signal was contin-
ued to decrease (Fig. 2C) with the late increase of a-synuclein bur-
den in MPP+-treated DA neurons (Fig. 2D), suggesting that the
downregulation of BPOZ-2 could be involved for the accumulation
of a-synuclein. Accordingly, our quantitative analyses further re-
vealed that the number of DA neurons expressing BPOZ was signif-
icantly low after 6 h (Fig. 2E) whereas polymerized a-syn-
immunoreactive cells were observed to be higher after 72 h and0
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+-stimulated mouse primary dopaminergic neurons. (A) Mouse primary neurons
hemical analyses of BPOZ-2 (green) and TH (red). (B) Mouse primary neurons were
n. Nuclei were stained with DAPI. Mean ﬂuorescent intensities of BPOZ-2 (C) and a-
togram represents the percent value of total number of BPOZ-2 expressing cells with
ynuclein-immunoreactive cells versus total number of DAPI-positive cells with MPP+
3570 A. Roy, K. Pahan / FEBS Letters 587 (2013) 3567–3574reached maximum at 96 h of MPP+ stimulation (Fig. 2F). Taken to-
gether, our results suggest that the downregulation of BPOZ-2
expression might be involved in the aggregation of a-synuclein
protein.
2.2. The necessary and sufﬁcient role of BPOZ-2 in the amelioration of
a-synucleinopathy
Next, we wanted to study the direct role of BPOZ-2 in the
expression of a-synuclein in mouse primary DA neurons. To con-
ﬁrm the role of BPOZ-2, we performed siRNA mediated knocking
down of BPOZ-2 (Fig. 3A) followed by the immunoblot analyses
of a-synuclein in MPP+-stimulated mouse primary DA neurons.
Interestingly, our immunoblot (Fig. 3B) and immunoﬂuorescence
data (Fig. 3C) revealed that the selective knocking down of BPOZ-
2 alone strongly upregulated the accumulation of a-synuclein olig-
omers equivalent to DA neurons treated with MPP+ only. The effectC
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be marginally higher in the presence of MPP+ (Fig. 3C and D), indi-
cating that the speciﬁc ablation of BPOZ-2 is sufﬁcient to establish
a-synucleinopathy in DA neurons. This effect is stunning and to
conﬁrm that effect, we performed a dose dependent study in which
mouse primary DA neurons were incubated with increasing con-
centrations of both control and BPOZ-2siRNA. Interestingly, we
found that the increasing doses of BPOZ-2 siRNA, but not control
siRNA, stimulated the appearance of punctuated a-synuclein inclu-
sions at 72 h of incubation suggesting the direct role of BPOZ-2 in
the abrogation of a-synuclein aggregates (Fig. 4A). Moreover, the
quantitative analyses of our immunoﬂuorescence results further
revealed that BPOZ-2 siRNA, but not control siRNA, alone strongly
stimulated the load of a-synuclein inclusions as well as the num-
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that selective knockdown of BPOZ-2 is sufﬁcient to generate a-syn-
uclein aggregation in DA neurons. Next we wanted to study the ef-
fect of BPOZ-2 overexpression in the amelioration of a-synuclein
aggregates in MPP+-treated DA neurons (Fig. 3E). Interestingly,
we observed that overexpression of BPOZ-2 signiﬁcantly attenu-
ated the accumulation of a-synuclein in MPP+-treated DA neurons
further suggesting the essential and pivotal role of BPOZ-2 in the
prevention of a-synucleinopathy in DA neurons.
2.3. BPOZ-2 inhibited the aggregation of a synuclein via post-
transcriptional, but not transcriptional modiﬁcation
So far, we observed that the selective knockdown of BPOZ-2 pri-
marily elevated the aggregation of a-synuclein protein in mouse
primary DA neurons. Since accumulation of a-synuclein is also
caused by the increased transcription of snca gene, next we wanted
to study if BPOZ-2 at all plays any role in the transcriptional inhi-
bition of a-synuclein gene in order to reduce the burden of a-syn-
uclein aggregates in DA neurons. In order to test that possibility,
we ﬁrst performed both semiquantitative and quantitative mRNA
analyses of a-synuclein in control siRNA- and BPOZ-2 siRNA-trea-
ted neurons (Fig. 5A) at 24, 48, and 72 h of stimulation with MPP+.
Interestingly we observed that BPOZ-2 siRNA was unable to induce
the level of a-synuclein mRNA in DA neurons as evident from our
semiquantitative RT-PCR analyses (Fig. 5 A). The effect was further
conﬁrmed by quantitative realtime PCR analyses (Fig. 5B and C).
Taken together our results suggest that BPOZ-2 is only involved
in the post-transcriptional stability, but not in the transcription
of a-synuclein molecule and thereby leads to the late formation
of a-synuclein aggregates in neuron.2.4. BPOZ-2 inhibited the aggregation of a synuclein in vivo in nigra of
MPTP-intoxicated vertebrate model of Parkinson’s disease
So far, we analyzed the effect of BPOZ-2 on the formation of a-
synuclein aggregates in mouse primary DA neuronal cultures and
that effect could be different in vivo in the brain. Therefore, next
we wanted to study the effect of BPOZ-2 on the accumulation of
a-syn in vivo in the nigra of MPTP-intoxicated mouse brain. First,
we performed a double immunoﬂuorescence analysis of a-synuc-
lein (green) and BPOZ-2 (red) in the nigra of mouse brain. We
observed strong downregulation of BPOZ-2 expression in the DA
neurons in the nigra of MPTP-treated mice, which was coupled
with the elevated level of a-synuclein aggregates suggesting the
negative correlation between BPOZ-2 expression and a-synuclein-
opathy in vivo in the nigra of mouse brain (Fig. 6A). According to
our immunoﬂuorescence analyses, we observed that the number
of BPOZ-2 positive and a-synuclein negative cells are higher in
the control brain and are signiﬁcantly low in MPTP-treated mouse
nigra as shown in red colored cells. On the other hand, we observed
signiﬁcantly higher number of a-synuclein positive but BPOZ-2
negative cells in the nigra of MPTP-treated mouse brain than the
nigra of control brain as shown in green colored cells suggesting
the essential role of BPOZ-2 in reducing the burden of a-synuclein
in vivo in brain. Since the load of a-synuclein aggregates has been
reported to be high in the brain of chronic animal model of PD, next
we performed the double immunoﬂuorescence analysis of BPOZ
and a-synuclein in the nigra of MPTP-induced chronic mouse
model of PD. As expected, we observed that nigra of chronic brain
expressed relatively higher loads of a-synuclein than acute nigra
with fewer cells expressing BPOZ-2. Next, we wanted to validate
our ﬁnding in MPTP-induced hemiparkinsonian primate model of
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expressed signiﬁcant amount of BPOZ-2 and the level decreased
when animals treated with MPTP. Moreover, we observed that
neurons containing the a-synuclein aggregate were totally devoid
of BPOZ-2 as shown by arrow head. Taken together, our results
indicate that BPOZ-2 indeed inhibits the aggregation of a-synuc-
lein in vivo in the nigra of MPTP-induced mouse brain of PD.
3. Discussion
Cytoplasmic aggregation of a-synuclein protein is the patholog-
ical hallmark PD as it inhibits the intracellular transport of
different proteins and metabolites leading to the axonal degenera-
tion and death of nigrostriatal DA neurons [15,16]. Therefore, the
removal of a-synuclein aggregates is a potential therapeutic
challenge in the treatment of PD. So far, the dysfunction of protea-
some–ubiquitin machinery in DA neurons is believed to be a major
contributing factor for the a-synucleinopathy and hence, the ubiq-
uitin enzyme complex is always under scanner in search of the
molecular mechanism for a-synuclein aggregation. However, there
is not much known about the ubiquitination machinery involved inthe degradation of a-synuclein protein. Our study ﬁrst time reveals
the involvement of BPOZ, an E3 ubiquitin ligase associated protein,
in the early events of a-synuclein aggregation. However, it would
be premature to comment that BPOZ-2 is involved in the degrada-
tion of a-synuclein via ubiquitin–proteasomal pathway, which re-
quires much rigorous experimental evidences. The role of BPOZ
protein in the pathogenesis of cancer has been reported before.
However, its role in the pathogenesis of neurodegenerative disor-
ders has not been studied so far. Our present manuscript ﬁrst time
reports the detection of this molecule in the DA neurons and also
highlights its protective role in the loss of DA neurons in PD. Our
results clearly demonstrate that BPOZ plays a critical role in the
survival of DA neurons in presence of PD pathology as its expres-
sion is strongly downregulated in presence of MPP+. The effect pre-
cedes much ahead of the accumulation of a-synuclein aggregates
in DA neurons indicating that its inhibition might be responsible
for the accumulation of a-synuclein protein in DA neurons. Our
time-dependent analyses of bpoz mRNA and protein expression
clearly indicate that the downregulation of BPOZ has a strong cor-
relation with the accumulation of a-synuclein protein. In agree-
ment with this fact, BPOZ siRNA alone stimulated the building up
of a-synuclein oligomers in DA neurons suggesting the direct
involvement of BPOZ in the a-synucleinopathy. While looking at
the mechanism, we observed that the siRNA knockdown of BPOZ
did not alter the mRNA expression of snca gene indicating that
BPOZ is not involved in the transcriptional regulation. Instead,
BPOZ is involved in the post translation regulation of a-synuclein
protein as our immunoblot analyses under similar treatment con-
dition signiﬁcantly increased the cellular burden of a-synuclein
protein in the cultured DA neurons. Since, BPOZ is a well-known
co-activator of E3 ubiquitin ligase that controls the turnover of
many biological proteins; it is obvious that similar mechanism of
protein degradation by BPOZ is impaired in MPP+-treated DA neu-
rons that leads to the formation of a-syn aggregates. Similar to our
cell culture studies, we observed that BPOZ expression was
strongly downregulated in the nigra of both acute and chronic
mouse model as well as in the primate model of PD. In all cases,
strong downregulation of BPOZ is accompanied with the elevated
expression of a-synuclein aggregates validating our hypothesis
in vivo in animal model.
BPOZ is an ankyrin rich scaffold protein that has been known to
anchor E3 ubiquitin ligases in order to catalyze the degradation of
the tumorigenic protein. Until now, no study had been done to
study its role in the regulation of neuronal function. It is not
known if this protein is involved in the survival and growth of neu-
rons in healthy as well as diseased brain. In that context, our pres-
ent study introduces BPOZ as a neuroprotective protein of DA
neurons when they are challenged to death in PD. Another
strength of our paper is that we have validated our ﬁnding
in vivo in different rodent and primate model of PD. We have
successfully shown that the downregulation of BPOZ-2 is truly in-
volved in the nigral accumulation of a-synuclein. The degradation
mechanism and proteins associated for the degradation of a-syn-
uclein is poorly understood. In that sense our study highlights
the possible role of BPOZ-2 protein in the degradation of a-synuc-
lein. However, we do not know if this molecule modulates the ac-
tion of parkin, a PD associated E3 ubiquitin ligase. However, recent
reports suggest that parkin interacts with CUL family of E3 ubiqui-
tin ligase [17], which is a well-known binding partner of BPOZ-2
[2,5]. It can be predicted that there might be a crosstalk between
BPOZ-2 and parkin via CUL family of ubiquitin ligase. Therefore,
the association of parkin with BPOZ is deﬁnitely an area of our fu-
ture interest and if we observe the association of BPOZ and parkin
modulates the catalytic action of parkin, then that will certainly
explain the reason for the dysfunction of parkin protein in pres-
ence of PD pathology.
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Fig. 6. The role of BPOZ-2 in the accumulation of a-synuclein protein in the nigra of MPTP-induced mouse and primate model of PD. Dual immunoﬂuorescence analyses of
BPOZ-2 (red) and a-syn (green) in the nigra of control and MPTP-intoxicated mice brains in acute (A) and chronic model (B) of PD. (C) Expression of BPOZ-2 (green) was
analyzed in TH-immunoreactive (red) nigra of MPTP-induced hemiparkinsonian monkey brain. (D) Dual immunoﬂuorescence analyses of BPOZ-2 (red) and a-syn (green) in
the nigra of control and hemiparkinsonian monkey brain. Arrow sign indicates the neurons deﬁcient with BPOZ-2 is associated with the accumulation of a-synuclin protein.
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4.1. Animals and reagents
Male C57 BL/6 mice were purchased from Jackson Laboratory
and maintained in the animal facility of Rush University Medical
Center. BPOZ-2 siRNA (Cat #sc-140786) was obtained from Santa-
cruz biotechnology, BPOZ-2 antibody (Cat #ab1077) was pur-
chased from Abcam, primers of RT-PCR and lipofectamine200
transfection reagents were purchased from Invitrogen.
4.2. Isolation of primary dopaminergic neurons
Nigra was dissected as a thin slice of ventral mesencephalon tis-
sue from E12.5 to 14 days old fetus and will be homogenized with
1 ml of trypsin for 5 min at 37 C followed by neutralization of
trypsin [18]. The single cell suspension of nigral tissue was plated
in the poly-D-lysine pre-coated 75 mm ﬂask and was allowed to
differentiate fully for 9–10 days before treatment [18–20].
4.3. Semiquantitative RT-PCR
Total RNA was isolated from DA neurons using Ultraspec-II RNA
reagent (Biotecx Laboratories, Inc., Houston, TX) following manu-
facturer’s protocol. To remove any contaminating genomic DNA,
total RNA was digested with DNase. RT-PCR was carried out as de-
scribed earlier [21,22] using a RT-PCR kit (Clontech, Mountain
View, CA) with following primers. BPOZ-2 sense 50GTGGGCAT
GGAACAGTGAGA30 and antisense 50TGTCCACCATCCAACGGAAG30.
Seven hundred seven bp long product was electrophoresed in
ethedium bromide containing 1.5% agarose gel and detected in
our bio-rad gel doc machine.4.4. Quantitative realtime PCR
Quantitative RT-PCR was performed using the ABI-Prism7700
sequence detection system (Applied Biosystems) as described
earlier [23]. Brieﬂy, reactions were performed in 96-well optical
reaction plates on cDNA equivalent to 50 ng of DNase-digested
RNA in a volume of 25 ll, containing 12.5 ll of SYBR Green Univer-
sal Master mix, nuclease free H2O, and forward and reverse prim-
ers following manufacturer’s protocol. Primers of BPOZ-1, BPOZ-2,
and GAPDH were purchased from Invitrogen. The mRNA expres-
sion of BPOZ-2 was normalized to the level of glyceraldehyde-3-
phosphate dehydrogenase mRNA. Data were processed by the
ABI Sequence Detection System 1.6 software and analyzed by anal-
ysis of variance.
4.5. SiRNA knockdpon of BPOZ-2
Mouse primary DA neuronal culture was transfected with 0.25–
0.5 lg of BPOZ-2 siRNA using lipofecatmine 2000 following manu-
facturers’ protocol under serum free condition. The efﬁciency of
transfection was increased with the use of neupherin reagent. After
4 h of transfection neurons were supplemented with serum
enriched media and after another 24 h neurons were treated with
MPP+.
4.6. Immunoﬂuorescence analysis
Immunocytochemistry was performed as described earlier
[24,25]. Brieﬂy, coverslips containing neurons cultured to 70–80%
conﬂuence were ﬁxed with chilled methanol (Fisher Scientiﬁc,
Waltham, MA) overnight, followed by two brief rinses with ﬁltered
PBS. Samples were blocked with 2% BSA (Fisher Scientiﬁc) in PBS
3574 A. Roy, K. Pahan / FEBS Letters 587 (2013) 3567–3574containing Tween 20 (Sigma–Aldrich) and Triton X-100 (Sigma–Al-
drich) for 30 min and incubated at room temperature under shak-
ing conditions for 6 h in PBS containing the following anti-mouse
primary Abs: BPOZ-2 (1:200; Cat #ab1077 Abcam), a-synuclein
(1:2000; Cat #610787 BD transduction laboratories), TH (1:1000,
Calbiochem). After four 15-min washes in ﬁltered PBS, slides were
further incubated with Cy2- or Cy5-labeled secondary Abs (all
1:200; Jackson ImmunoResearch Laboratories, West Grove, PA)
for 1 h under similar shaking conditions. Following four 15-min
washes with ﬁltered PBS, cells were incubated for 4–5 min with
DAPI (1:10000; Sigma–Aldrich). The samples were run in Xylene
(Fisher Scientiﬁc) gradient, mounted, and observed under a Bio-
Rad MRC1024ES confocal laser-scanning microscope.
4.7. Immunoblot analysis
Immunoblot analysis was conducted as described earlier [25].
Brieﬂy, cells were scraped in lysis buffer, analyzed for protein con-
centration via the Bradford method (Bio-Rad). SDS sample buffer
was added to 40–60 lg total protein and boiled for 5 min. Dena-
tured samples were electrophoresed on NuPAGE Novex 4–12%
Bis–Tris gels (Invitrogen), transferred onto a nitrocellulose mem-
brane (Bio-Rad) using the Thermo-Pierce Fast Semi-Dry Blotter,
washed for 15 min in TBST, blocked for 1 h in TBST containing
BSA. Next, membranes were incubated overnight at 4 C under
shaking conditions with primary Abs followed by thorough wash
and incubation with 2 Abs for 1 h at room temperature, washed
for onemore hour, and visualized under the Odyssey Infrared Imag-
ing System (Li-COR, Lincoln, NE). Relative density of immunoblots
wasmeasured by taking individual pixel value followed by the divi-
sion with their respective actin value in image J software suite.
4.8. Development of different animal models used for this study
Development of chronic mouse model was described ear-
lier[26]. In this model, six- to eight-week-old male C57BL/6 mice
received 10 injections of MPTP (subcutaneously [s.c.]; 25 mg/kg
body weight) together with 10 injections of probenecid (intraper-
itoneally [i.p.]; 25 mg/kg body weight) for ﬁve weeks. For acute
model, mice received four intraperitoneal injections of MPTP-HCl
(18 mg/kg of free base; Sigma–Aldrich) in saline at 2 h intervals
[27,28]. The development of hemiparkinsonian monkey model
was described elsewhere[29]. Animal maintaining and experi-
ments were in accordance with National Institutes of Health guide-
lines and were approved by the Institutional Animal Care and Use
Committee of Rush University Medical Center.
4.9. Statistical analysis
Values are expressed as means ± S.D. of at least three indepen-
dent experiments. Statistical analyses for differences were per-
formed via one-way ANOVA, followed by Tukey’s or Scheffe’s
post hoc tests using SPSS 19 (IBM, Armonk, NY). The criterion for
statistical signiﬁcance was P < 0.05.
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